ArticleJournal of clinical medicine2022
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to the healing of hepatogenic ulcer.BMC gastroenterology · 2025Trial
- Prevalence of primaryGut microbes · 2026Review
- A Nationwide Trend Analysis ofGut and liver · 2026Article
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Therapeutic advances and future directions inFrontiers in microbiology · 2025Review
- Beyond antibiotics: probiotics as a promising ally againstFrontiers in pharmacology · 2025Review
- The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland.European journal of gastroenterology & hepatology · 2024Article
- Single-Arm, Prospective, Interventional Study ofJournal of clinical medicine · 2024Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.United European gastroenterology journal · 2023Article
- Rescue therapy for refractoryTherapeutic advances in gastroenterology · 2023Review
- Rifabutin as salvage therapy forWorld journal of gastroenterology · 2022Review
- Treatment of refractoryFrontiers in microbiology · 2022Review
- European Registry onFrontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
- Article
- Practice guidelines for the management ofSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst-line
methodsInternational multicentre prospective non-interventional European Registry on
resultsOverall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation.
conclusionRifabutin-containing therapy represents an effective and safe strategy after one or even several failures of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.